Patrick M. Schlievert

Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN.

Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN.

Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN.

Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN.

Hennepin Life Sciences LLC operates as a clinical-stage biotechnology company which focuses on identifying and developing antimicrobial therapeutics. It is advancing its novel antimicrobial, GML Gel, for local administration to prevent and treat CA-UTIs caused by ESKAPE pathogens in hospitals and long-term care centers. The company was founded by Patrick M. Schlievert, William Merrill Faulkner and Douglas Wicks in 2009 and is headquartered in Plymouth, MN.